Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer

Table 2 Differences in the clinicopathological characteristics in eligible omeprazole users and non-eligible omeprazole users

Characteristics	Total	EOU		P value
		Non	Yes
Sex
Male	90	46	44	0.59
Female	35	16	19
Age (yr)
< 60	73	37	36	0.77
≥ 60	52	25	27
BMI
< 25	100	47	53	0.25
≥ 25	25	15	10
Tumor size (cm)
≤ 3	49	24	25	0.95
3-6	61	30	31
≥ 6	15	8	7
Tumor grade
1	28	14	14	0.23
2	88	46	42
3	9	2	7
cTNM
II	39	22	17	0.31
III	86	40	46
CEA (ng/mL)
< 5	62	28	34	0.47
≥ 5	58	30	28
CA19-9 (U/mL)
< 35	102	50	52	0.72
≥ 35	18	8	10
TGR
0	39	23	16	0.25
1	15	8	7
2	20	12	8
3	24	9	15
4	27	10	17
CRT efficacy
Poor	74	43	31	0.02
Good	51	19	32
ypTNM
ypcr	25	9	16	0.34
I	26	16	10
II	40	20	20
III	34	17	17
Adjuvant CT
No	21	9	12	0.5
Yes	104	53	51
Recurrence
No	92	46	46	0.66
Yes	33	16	17

EOU: Eligible OME users; non-EOU: Non-eligible OME users; BMI: Body mass index; TGR: Tumor regression grade; adjuvant CT: Adjuvant chemotherapy.